SR Pharma plc acquires the assets of Rodaris Pharmaceuticals          

London, 3 April 2003 - SR Pharma plc (LSE: SPA) today announced its acquisition
of over 250 compounds from Rodaris Pharmaceuticals. Several of these
patent-protected and well-characterised molecules have demonstrated potential
activity in the treatment of autoimmune diseases, diabetes, obesity and the
diagnosis of pre-eclampsia. SR Pharma is currently reviewing the pre-clinical
and clinical data accompanying these new product candidates and evaluating
their commercial potential with a view to early out-licensing. In a related
move, SR Pharma acquired full ownership of Innopeg, a 50:50 joint venture
company with Rodaris in late-2002. Both acquisitions involved nominal financial
considerations.

Chief Operating Officer of SR Pharma Dr. David Kennard said: "These
well-characterised compounds complement very well our strategy of developing
medicines in diseases with a well-defined immunological basis. Having
collaborated with Rodaris for a number of years, SR Pharma is well placed to
extract significant value from this acquisition."

ENDS

About SR Pharma
SR Pharma plc (www.srpharma.com) was founded in 1992 and develops novel
medicines based on an improved understanding of the role played by the immune
system in combating disease. The company's proprietary M. vaccae-based
technology is the source of a number of product developments. SR Pharma is
currently evaluating SRP299 and AVAC(TM) for the treatment of asthma and atopic
dermatitis. The company is also investigating SRL172 as a vaccine adjuvant in
cancer and infectious diseases. These products enhance the immune responses
needed to combat cancer and infection, while regulating those that mediate
allergies.

For further information please contact:
Steeve Lamontagne, SR Pharma plc
Tel: +44 (0) 20 7307 1628
Email: s.lamontagne@srpharma.com

                                    Page 2                                     



END